Moe Alsumidaie: Mitapivat Challenges the Transfusion-Centric Model of Thalassaemia Care
Moe Alsumidaie, Chief Editor at The Clinical Trial Vanguard, Head of Research at CliniBiz, shared a post on LinkedIn:
“For decades, thalassaemia meant one thing for patients: a transfusion appointment every three to four weeks, year after year, for life.
That schedule just got its first real challenger.
Agios Pharmaceuticals built the ENERGIZE-T Phase 3 trial around a single question: can one twice-daily oral tablet meaningfully reduce how often patients need someone else’s blood to survive?
Across 258 patients, 48 weeks of blinded treatment, and both alpha and beta thalassaemia, the answer was yes.
The FDA agreed, approving mitapivat in December 2025 as the first oral treatment for anemia in adults with beta-thalassaemia and the first drug approval of any kind for adults with alpha-thalassaemia.
The part the headline misses: the trial’s design is the real story.
Agios chose transfusion burden reduction as the primary endpoint, not hemoglobin response, not a surrogate.
That is a harder target, and the FDA accepting it signals something bigger for the field.
Any sponsor now running a chronic transfusion program will face a benchmark of 258 patients and 48 weeks of clean data.
A shorter trial will need a pre-negotiated justification.
The bar moved on December 23, 2025, and it is not moving back.
The economics make this urgent.
Annual healthcare costs for transfusion-dependent thalassaemia patients in the U.S. run over 137,000 dollars per patient.
A therapy that compresses transfusion frequency compresses those cost curves for decades.
Are we building enough health economics evidence into rare disease Phase 3 designs from the start, or are we still treating it as a post-approval problem?”
Stay updated with Hemostasis Today.
-
Nov 4, 2026, 15:59Alessandra Bosch: A Successful Patient Day for the Bleeding Disorders Community in Zürich
-
Nov 4, 2026, 15:47Wolfgang Miesbach: Targeting Hepatic Endothelial Cells for Lentiviral Gene Therapy in Haemophilia A
-
Nov 4, 2026, 15:20Augustina Isioma Ikusemoro: Before You Transfuse, Think PBM
-
Nov 4, 2026, 14:23Advancing Hemophilia Care Through Global Research – WFH
-
Nov 4, 2026, 14:12Jean-Jacques Kiladjian: From JAK Inhibitor-Associated Skin Cancers to Laboratory Discovery
-
Nov 4, 2026, 13:59Rita Li: ASH 2026 Abstract Achievement Award for Gut Microbiome Research
-
Nov 4, 2026, 13:38Omid Seidizadeh: Improving Access to von Willebrand Disease Diagnosis and Treatment Across Europe
-
Nov 4, 2026, 13:38Fiona Robinson: NBDF Webinar Explores the Practical Challenges of Hemophilia Gene Therapy
-
Nov 4, 2026, 13:33Reza Shojaei: AI-Driven Innovation in Blood and Plasma Services